An Abbreviated New Drug Application (ANDA) is the application FDA reviews to approve a generic version of an already-approved brand-name drug. It is called “abbreviated” because, unlike a full New Drug Application (NDA), an ANDA generally does not need to include new preclinical (animal) and clinical (human) safety and efficacy data. Instead, the applicant demonstrates that the generic product is bioequivalent to the already-approved reference drug — that it delivers the same active ingredient, at the same dose, into the bloodstream at essentially the same rate and extent. FDA relies on the reference drug’s existing safety and efficacy record rather than requiring it to be re-established from scratch.
For research administrators and technology transfer professionals, the ANDA pathway matters at a specific, later stage of the university-to-market pipeline: it is not the route by which a novel, university-discovered compound first reaches patients (that is an NDA or, for biologics, a Biologics License Application (BLA)). The ANDA pathway becomes relevant once a drug’s patent and regulatory exclusivity have expired, or are approaching expiry, and a licensee wants to manufacture and sell a generic version — which can itself be a downstream licensing opportunity for a university that holds a compound patent nearing the end of its exclusivity period, or a consideration when negotiating exclusivity/field-of-use terms in an original license.
Statutory basis: the Hatch-Waxman Act
The ANDA pathway was created by the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Act, which added Section 505(j) to the Federal Food, Drug, and Cosmetic Act. Before 1984, a generic manufacturer generally had to independently prove safety and effectiveness even for a drug already on the market — Hatch-Waxman replaced that duplication with the bioequivalence standard. The trade-off built into the same law is a countervailing benefit for brand manufacturers: patent term restoration (extending patent life to partially compensate for time consumed by FDA review) and statutory data exclusivity periods that can delay generic entry regardless of patent status. FDA notes that generics accounted for roughly 19% of U.S. prescriptions at the time of Hatch-Waxman’s enactment; that figure is now over 90%.
What an ANDA applicant must demonstrate
An ANDA does not stand alone — it references an already-approved brand-name drug, called the Reference Listed Drug (RLD). To be approved, the applicant must show the generic product is the same as the RLD in each of the following respects:
- Active ingredient(s) — the same active moiety.
- Strength — the same dosage strength.
- Dosage form and route of administration — e.g., an oral tablet cannot be approved as generic to an injectable of the same drug.
- Labeling — conditions of use consistent with the RLD’s approved labeling (with limited, permitted differences, e.g., where a use is still protected by unexpired exclusivity).
- Bioequivalence — typically demonstrated through pharmacokinetic studies comparing how the generic and the RLD are absorbed into the bloodstream, though FDA also permits other methods (e.g., in vitro dissolution comparisons) where scientifically appropriate for the drug class.
Manufacturing quality is reviewed separately: the applicant’s facility must pass FDA’s current Good Manufacturing Practice (cGMP) inspection requirements, the same baseline that applies to brand manufacturing.
Patent certification: Paragraphs I through IV
Because an ANDA references a drug that may still be under patent, applicants must certify their position with respect to each patent FDA’s Orange Book (“Approved Drug Products with Therapeutic Equivalence Evaluations”) lists against the RLD. There are four possible certifications:
- Paragraph I — no patent information has been filed for the drug.
- Paragraph II — the listed patent has already expired.
- Paragraph III — the applicant will not market the generic until the listed patent expires.
- Paragraph IV — the applicant asserts the listed patent is invalid, unenforceable, or will not be infringed by the generic product.
A Paragraph IV certification is the one that routinely produces litigation: it requires the ANDA applicant to notify the patent holder, who then has 45 days to sue for patent infringement. If suit is filed within that window, FDA approval of the ANDA is automatically stayed for up to 30 months (or until the litigation resolves, if sooner). This is a distinct legal and commercial risk profile from a standard NDA review, and it is one reason license agreements covering compounds with generic-entry potential often address Paragraph IV exposure, notice obligations, and cost/control of any resulting litigation explicitly.
How an ANDA differs from an NDA and a BLA
| Pathway | Statutory basis | Core requirement | Typical applicant scenario |
|---|---|---|---|
| NDA | FD&C Act § 505(b) | Full preclinical and clinical safety/efficacy data package for a new drug (or, under 505(b)(2), partial reliance on existing published/FDA data plus some new studies) | Sponsor bringing a novel small-molecule drug — e.g., a university-licensed compound — to market for the first time |
| ANDA | FD&C Act § 505(j) | Bioequivalence to an already-approved Reference Listed Drug; no new efficacy trials | Generic manufacturer entering the market after patent/exclusivity expiry |
| BLA | Public Health Service Act § 351 | Full safety/efficacy/purity/potency data package for a biologic | Sponsor of a biologic (vaccine, monoclonal antibody, cell/gene therapy); the closest analog for a biologic “generic” is a biosimilar application under § 351(k), a separate, distinct pathway from the ANDA — biosimilars are not approved via ANDA because bioequivalence in the small-molecule sense does not translate directly to complex biologic molecules |
Review process and user fees
ANDAs are reviewed under the Generic Drug User Fee Amendments (GDUFA) framework, which funds FDA’s generic-drug review program through fees paid by applicants and facilities and sets negotiated review-performance goals between FDA and industry. Facilities involved in generic manufacturing (finished dosage form and active pharmaceutical ingredient sites) also pay annual facility fees under the same framework. Exact fee amounts and review-goal percentages are renegotiated periodically (GDUFA is reauthorized on a multi-year cycle alongside the other FDA user-fee programs) — an applicant or licensing office should confirm current figures directly against FDA’s GDUFA program page rather than relying on a fixed number, since these change with each reauthorization cycle.
Why this matters for university technology transfer
A university technology transfer office rarely files an ANDA directly — that is almost always the licensee’s or a downstream generic manufacturer’s regulatory activity, not the institution’s. Where the ANDA pathway becomes relevant to tech transfer practice:
- Patent-life planning in licensing negotiations. Because Hatch-Waxman patent term restoration and data exclusivity periods interact directly with when generic competition (and ANDA filings) can begin, licensing terms — royalty step-downs, exclusivity duration, sublicensing rights — are often structured with the eventual generic-entry date in mind.
- Orange Book listing obligations. A licensee that obtains NDA approval for a university-licensed compound is the party responsible for listing relevant patents in the Orange Book; the university, as patent owner, should confirm its licensee is meeting this obligation, since an unlisted patent generally cannot trigger the Paragraph IV notice-and-stay mechanism.
- Post-exclusivity licensing opportunities. Once branded exclusivity nears its end, a university that retains rights in certain fields of use, or that holds related formulation or manufacturing-process patents, may itself become a licensor to generic manufacturers — a genuinely distinct negotiation from the original innovator license.
- Invention reporting continuity. Under the Bayh-Dole Act, a university’s original invention disclosure and iEdison utilization reporting obligations do not end when a licensee’s product reaches an ANDA-eligible stage of its lifecycle; institutions should track a licensed compound’s regulatory status as part of ongoing Bayh-Dole compliance, not treat reporting as a one-time event at initial licensing.
Frequently asked questions
Does an ANDA require new clinical trials?
Generally no. The core requirement is demonstrating bioequivalence to the Reference Listed Drug, typically via pharmacokinetic comparison studies rather than the large-scale safety/efficacy trials an NDA requires. FDA guidance documents specify acceptable bioequivalence study designs on a product-class basis.
Is an ANDA the same thing as a biosimilar application?
No. ANDAs (FD&C Act § 505(j)) apply to small-molecule generic drugs. Biologics follow a separate pathway — an original BLA under Public Health Service Act § 351(a), with a distinct “biosimilar” abbreviated pathway under § 351(k). The two frameworks are not interchangeable, and complex biologics are not approved as generics via ANDA.
What triggers the 30-month stay in ANDA litigation?
A Paragraph IV certification, followed by the patent holder filing an infringement suit within 45 days of receiving notice, triggers an automatic stay of FDA approval for up to 30 months (or until the litigation concludes, if earlier) — a Hatch-Waxman mechanism specific to this pathway.
Who typically files the ANDA — the university or the licensee?
In nearly all cases, the licensee (a generic manufacturer or, for the original branded product, the innovator licensee) files with FDA, not the university. The university’s role is upstream: the underlying patent(s), the license agreement’s terms governing exclusivity and generic entry, and ongoing Bayh-Dole invention-reporting obligations.
See also: Bayh-Dole Act, Patent Licensing: Exclusive Terms, Royalties, and Startup vs. Established Deals, iEdison: Invention Reporting and Utilization Reports, How Long Do Patents Last?, and Industry-University Research Partnerships.
